HomeCompareTHAR vs KMB

THAR vs KMB: Dividend Comparison 2026

THAR yields 57.64% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 THAR wins by $533.9K in total portfolio value
10 years
THAR
THAR
● Live price
57.64%
Share price
$3.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$579.9K
Annual income
$131,396.64
Full THAR calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — THAR vs KMB

📍 THAR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTHARKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, THAR + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
THAR pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

THAR
Annual income on $10K today (after 15% tax)
$4,899.14/yr
After 10yr DRIP, annual income (after tax)
$111,687.14/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, THAR beats the other by $107,248.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of THAR + KMB for your $10,000?

THAR: 50%KMB: 50%
100% KMB50/50100% THAR
Portfolio after 10yr
$312.9K
Annual income
$68,309.49/yr
Blended yield
21.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

THAR
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
0.4
Piotroski
2/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

THAR buys
0
KMB buys
0
No recent congressional trades found for THAR or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTHARKMB
Forward yield57.64%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$579.9K$45.9K
Annual income after 10y$131,396.64$5,222.34
Total dividends collected$477.1K$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold

Year-by-year: THAR vs KMB ($10,000, DRIP)

YearTHAR PortfolioTHAR Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$16,464$5,763.69$11,314$614.45+$5.2KTHAR
2$26,485$8,868.37$12,867$760.19+$13.6KTHAR
3$41,671$13,332.91$14,713$945.27+$27.0KTHAR
4$64,194$19,605.90$16,924$1,181.90+$47.3KTHAR
5$96,915$28,226.79$19,596$1,486.64+$77.3KTHAR
6$143,525$39,826.39$22,850$1,882.16+$120.7KTHAR
7$208,694$55,122.07$26,849$2,399.80+$181.8KTHAR
8$298,210$74,907.23$31,812$3,083.36+$266.4KTHAR
9$419,119$100,035.01$38,033$3,994.72+$381.1KTHAR
10$579,854$131,396.64$45,918$5,222.34+$533.9KTHAR

THAR vs KMB: Complete Analysis 2026

THARStock

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Full THAR Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this THAR vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

THAR vs SCHDTHAR vs JEPITHAR vs OTHAR vs KOTHAR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.